论文部分内容阅读
目的:探讨基质金属蛋白酶(MMP)-9及其抑制因子(TIMP)-1与急性冠状动脉综合征(ACS)患者冠状动脉病变的关系。方法:采用夹心酶联免疫法测定42例ACS患者和25例非冠心病对照者血清MMP-9及TIMP-1水平,并进行对比分析,并对ACS患者中的不稳定型心绞痛(UAP)亚组患者血清MMP-9及TIMP-1水平与冠状动脉病变Califf危险积分作相关分析。结果:ACS组MMP-9较对照组明显增高(P<0.01),而TIMP-1则较对照组显著降低(P<0.01);UAP患者血清MMP-9与冠状动脉病变积分呈明显正相关(r=0.770,P<0.01),血清TIMP-1则与冠状动脉病变积分呈明显负相关(r=-0.669,P<0.01)。结论:MMP-9及TIMP-1与急性冠状动脉综合征患者冠状动脉病变有关,可作为判断其病变程度的指标之一。
Objective: To investigate the relationship between matrix metalloproteinase (MMP) -9 and its inhibitor of metalloproteinase (TIMP) -1 and coronary artery disease in patients with acute coronary syndrome (ACS). Methods: The levels of serum MMP-9 and TIMP-1 in 42 patients with ACS and 25 patients with non-coronary heart disease were measured by sandwich enzyme-linked immunosorbent assay. The levels of serum MMP-9 and TIMP-1 in patients with ACS were compared. Correlation analysis between serum MMP-9 and TIMP-1 levels and Califf risk score in patients with coronary artery disease. Results: The levels of MMP-9 in ACS group were significantly higher than those in control group (P <0.01), but TIMP-1 was significantly lower than that in control group (P <0.01). Serum MMP-9 level was positively correlated with coronary artery disease r = 0.770, P <0.01). The serum level of TIMP-1 was negatively correlated with coronary artery disease (r = -0.669, P <0.01). Conclusion: MMP-9 and TIMP-1 may play an important role in the diagnosis of coronary artery disease in patients with acute coronary syndrome.